Pharma CEO/Top Executives Global Response to COVID-19 - Virtual Press Briefing
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis.
Watch More
COVID-19
As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19.
Read More
IFPMA Note for Guidance on Patient and Patient Organization Interactions
Patient groups and pharma industry collaborate on a new guidance note on best practices for interaction
Read more
Global Health Progress - Collaborating for a sustainable future
Global Health Progress is an interactive knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry &; more than 850 diverse partners to support the SDGs & drive cross-sector collaboration. Explore our collaborations & learn more
Explore
Achieving a Healthier and Sustainable Future for All - Policy Perspectives on Universal Health Coverage from the Innovative Biopharmaceutical Industry
Read More
Stepping up the Fight: Industry Collaboration to End HIV, Tuberculosis and Malaria
Now is the time to step up our fight against HIV, TB and malaria — we must do more, innovate more, and most importantly, partner more.
Read More
Thought Leader Series on Vaccines
In this special series on vaccines, IFPMA invites key opinion leaders to advance thinking and ideas on key issues that can drive efforts to allow the “miracle” of life-saving vaccines to reach all.
Read More
New IFPMA Code of Practice 2019
New IFPMA Code of Practice will enter into force on 1st January 2019
New CodeIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Global Health Progress – Collaborating for a sustainable future
Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry and more than 850 partners to support the SDGs. Users can explore collaborations by SDG target, disease area, program strategy, and more. Users are also encouraged to connect with partners via the platform...
Read More
Health for All in Africa - Our collaborations supporting the SDGs
Read More
Pharma CEO/Top Executives Global Response to COVID-19 - Virtual Press Briefing - 19 March 2020 (Video)
Read More
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
5 Questions to .... five leading biopharmaceutical company CEOs and top executives on the COVID-19 Pandemic
This was originally published in Pharma Boardroom on Wednesday, 1 April, 2020. The CEOs and top executives, David Ricks, Chairman and Chief Executive Officer, Eli Lilly & Co and IFPMA President, Severin Schwan, Chief Executive Officer, Roche, Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, David Loew, Executive Vice-President, Sanofi Pasteur and Rajeev Venkayya, President, Global Vaccines Business Unit, Takeda took part in a virtual...
Read More
Interview - BBC World Newshour - Biopharmaceutical industry commitments on COVID-19
Thomas Cueni, IFPMA Director General, spoke to BBC Newshour on 19 March about the commitments made by the global pharmaceutical industry in addressing the COVID-19 global health crisis. Industry has the tools and solutions to fight and defeat the novel strain of coronavirus. In this unique situation, industry commits to tackle this issue collaboratively - not just among the industry, but with WHO and with other health agencies. There has already been an intense and...
Read More
The global biopharmaceutical industry’s united front against COVID-19
In recent weeks, we have seen an unprecedented rapid response from governments, international organisations, health care professionals, the biopharmaceutical industry and many others to respond to one of the biggest global health crisis the world has experienced in recent decades: the novel coronavirus, or so-called COVID-19. Both professionally but also personally I think it's remarkable how far we have come in two months. R&D efforts...
Read MoreLatest Tweets
